Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.45 |
| ▸ | GPR132 | Q9UNW8 | 4/20 | 0.45 |
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.43 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.43 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29413325 | 1.00 | MME (0.49) | MMEKDM4EKISS1RGPR132CTSC | |
| Trifluoroacetic Acid SCHEMBL2367272 | 0.93 | MME (0.46) | MMEKDM4EKISS1RGPR132CTSC | |
| SCHEMBL4198783 | 0.92 | GPR132 (0.52) | MMEKDM4EGPR132CTSCECE1 | |
| SCHEMBL29615239 | 0.92 | GPR132 (0.51) | MMEKISS1RGPR132CTSCTBXAS1 | |
| SCHEMBL31542110 | 0.91 | BACE1 (0.46) | MMEKISS1RGPR132TBXAS1 | |
| SCHEMBL30509011 | 0.89 | GPR132 (0.50) | MMEKDM4EKISS1RGPR132HDAC8 | |
| SCHEMBL30685124 | 0.89 | MME (0.50) | MMEKDM4EGPR132CTSCECE1 | |
| SCHEMBL29743017 | 0.89 | ECE1 (0.51) | MMEKDM4EGPR132CTSCECE1 | |
| SCHEMBL29816805 | 0.88 | KISS1R (0.52) | MMEKISS1RGPR132 | |
| SCHEMBL29375944 | 0.86 | NAALAD2 (0.51) | GPR132NAPRTTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120121745-A | Method for detecting degarelix acetate impurity | 苏州天马医药集团天吉生物制药有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-117683093-A | Method for solid phase synthesis of ganirelix by fragment method | 中肽生化有限公司 | 2024-03-12 | — | — | CN | claimed |
| WO-2025202368-A1 | GNRH ANTAGONIST FORMULATION | DEBIOPHARM INTERNATIONAL SA (CH) | 2025-10-02 | — | — | WO | disclosed |
| CN-120121745-A | Method for detecting degarelix acetate impurity | 苏州天马医药集团天吉生物制药有限公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4512389-A2 | DEGARELIX DRUG PRODUCT | Ferring B.V. (NL) | 2025-02-26 | — | — | EP | disclosed |
| US-12098218-B2 | Process for the manufacture of degarelix and its intermediates | Fresenius Kabi iPSUM S.r.l (IT) | 2024-09-24 | — | — | US | disclosed |
| CN-118561901-A | Compound containing bis ((siloxy) phenyl) methane structure and preparation method and application thereof | 南京工业大学 | 2024-08-30 | — | — | CN | disclosed |
| EP-2854831-B1 | MANUFACTURE OF DEGARELIX | FERRING BV (NL) | 2024-07-10 | — | — | EP | disclosed |
| CN-117683093-A | Method for solid phase synthesis of ganirelix by fragment method | 中肽生化有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-112250735-B | Salt conversion method of cetrorelix | 开封明仁药业有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-109929007-B | Preparation method of degarelix key dipeptide intermediate | 连云港恒运药业有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-109929012-B | Preparation method of degarelix key tetrapeptide intermediate | 连云港恒运药业有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-11510962-B2 | Manufacture of degarelix | FERRING B.V. (NL) | 2022-11-29 | — | — | US | disclosed |
| CN-114456236-A | Preparation method of degarelix acetylated impurities | 深圳市健翔生物制药有限公司 | 2022-05-10 | — | — | CN | disclosed |
| EP-3981781-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi iPSUM S.r.l. (IT) | 2022-04-13 | — | — | EP | disclosed |
| CN-108779150-B | Preparation method of degarelix and intermediate thereof | 费森尤斯卡比依普莎姆责任有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-11260102-B2 | Manufacture of Degarelix | FERRING B.V. (NL) | 2022-03-01 | — | — | US | disclosed |
| US-20220033443-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi iPSUM S.r.l (IT) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11260102-B2 | Manufacture of Degarelix | PGA5, GIPR, LPXN | MME 641/4885KDM4E 1132/4885KISS1R 563/4885 |
| US-20220033443-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | ANPEP, DNPEP, NPPA | MME 256/4885KDM4E 1693/4885KISS1R 1549/4885 |
| US-12098218-B2 | Process for the manufacture of degarelix and its intermediates | ANPEP, DNPEP, NPPA | MME 256/4885KDM4E 1693/4885KISS1R 1549/4885 |
| US-11510962-B2 | Manufacture of degarelix | PGA5, GIPR, LPXN | MME 708/4885KDM4E 1167/4885KISS1R 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.